ArticleNature medicine2009
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase.
Article in Nature medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 129 citations in OpenAlex.
- Recent advances in non-invasiveBiomaterials science · 2025Review
- Host Interactions with Engineered T-cell Micropharmacies.Cancer immunology research · 2023Article
- Genetically targeted chemical assembly of polymers specifically localized extracellularly to surface membranes of living neurons.Science advances · 2023Article
- Host-cell Interactions of Engineered T cell Micropharmacies.bioRxiv : the preprint server for biology · 2023Article
- Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.Blood · 2023Article
- Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?Journal for immunotherapy of cancer · 2022Review
- Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation.Molecular imaging and biology · 2022Review
- Engineering CAR-T cells to activate small-molecule drugs in situ.Nature chemical biology · 2022Article
- Imaging CAR T-cell kinetics in solid tumors: Translational implications.Molecular therapy oncolytics · 2021Article
- Introducing a new reporter gene, membrane-anchoredMolecular therapy oncolytics · 2021Article
- Bioluminescent Imaging Systems for Assay Developments.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2021Review
- Seeing (and Using) the Light: Recent Developments in Bioluminescence Technology.Cell chemical biology · 2020Review
- Article
- Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging.Cancer gene therapy · 2020Article
- Spatial and temporal tracking of cardiac exosomes in mouse using a nano-luciferase-CD63 fusion protein.Communications biology · 2020Article
- Improved trafficking and expression of luminopsins for more efficient optical and pharmacological control of neuronal activity.Journal of neuroscience research · 2020Article
- Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency.Cancer immunology research · 2019Article
- Molecular Imaging with Reporter Genes: Has Its Promise Been Delivered?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Ultrasound imaging of gene expression in mammalian cells.Science (New York, N.Y.) · 2019Article
- New Developments in Imaging Cell-Based Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
We developed a new approach to bioluminescent T cell imaging using a membrane-anchored form of the Gaussia luciferase (GLuc) enzyme, termed extGLuc, which we could stably express in both mouse and human primary T cells. In vitro, extGLuc+ cells emitted significantly higher bioluminescent signal when compared to cells expressing GLuc, Renilla luciferase (RLuc) or membrane-anchored RLuc (extRLuc). In vivo, mouse extGLuc+ T cells showed higher bioluminescent signal when compared to GLuc+ and RLuc+ T cells. Application of this imaging approach to human T cells genetically modified to express tumor-specific chimeric antigen receptors (CARs) enabled us to show in vivo CAR-mediated T cell accumulation in tumor, T cell persistence over time and concomitant imaging of T cells and tumor cells modified to express firefly luciferase. This sensitive imaging technology has application to many in vivo cell-based studies in a wide array of mouse models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.